219 related articles for article (PubMed ID: 36309918)
1. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
Yang C; Guo G; Li B; Zheng L; Sun R; Wang X; Deng J; Jia G; Zhou X; Cui L; Guo C; Zhou X; Leung PSC; Gershwin ME; Shang Y; Han Y
Hepatol Int; 2023 Feb; 17(1):237-248. PubMed ID: 36309918
[TBL] [Abstract][Full Text] [Related]
2. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
3. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
4. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
6. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.
Murillo Perez CF; Ioannou S; Hassanally I; Trivedi PJ; Corpechot C; van der Meer AJ; Lammers WJ; Battezzati PM; Lindor KD; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Gulamhusein A; Ponsioen CY; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Parés A; Londoño MC; Janssen HLA; Invernizzi P; Vuppalanchi R; Hirschfield GM; Hansen BE; Levy C;
Liver Int; 2023 Jul; 43(7):1497-1506. PubMed ID: 37157905
[TBL] [Abstract][Full Text] [Related]
7. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
[TBL] [Abstract][Full Text] [Related]
8. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA.
Li J; Lu M; Zhou Y; Bowlus CL; Lindor K; Rodriguez-Watson C; Romanelli RJ; Haller IV; Anderson H; VanWormer JJ; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Wu KH; Trudeau S; Rupp LB; Melkonian C; Gordon SC;
Dig Dis Sci; 2022 Aug; 67(8):4170-4180. PubMed ID: 34499271
[TBL] [Abstract][Full Text] [Related]
10. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C; Lemoinne S; Soret PA; Hansen B; Hirschfield G; Gulamhusein A; Montano-Loza AJ; Lytvyak E; Pares A; Olivas I; Eaton JE; Osman KT; Schramm C; Sebode M; Lohse AW; Dalekos G; Gatselis N; Nevens F; Cazzagon N; Zago A; Russo FP; Floreani A; Abbas N; Trivedi P; Thorburn D; Saffioti F; Barkai L; Roccarina D; Calvaruso V; Fichera A; Delamarre A; Sobenko N; Villamil AM; Medina-Morales E; Bonder A; Patwardhan V; Rigamonti C; Carbone M; Invernizzi P; Cristoferi L; van der Meer A; de Veer R; Zigmond E; Yehezkel E; Kremer AE; Deibel A; Bruns T; Große K; Wetten A; Dyson JK; Jones D; Dumortier J; Pageaux GP; de Lédinghen V; Chazouillères O; Carrat F;
Hepatology; 2024 Jan; 79(1):39-48. PubMed ID: 37399238
[TBL] [Abstract][Full Text] [Related]
11. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
14. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
15. Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
Chang JI; Kim JH; Sinn DH; Cho JY; Kim KM; Oh JH; Park Y; Sohn W; Goh MJ; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2023 Jul; 17(4):620-628. PubMed ID: 36999383
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
17. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
[TBL] [Abstract][Full Text] [Related]
18. A new and simple score to predict adequate and deep response to ursodeoxycholic acid in patients with primary biliary cholangitis: the ALP-A score.
Cançado GGL; Gomes NMF; Couto CA; Cançado ELR; Terrabuio DRB; Villela-Nogueira CA; Braga MH; Nardelli MJ; Faria LC; Oliveira EMG; Rotman V; Oliveira MB; Cunha SMCFD; Mazo DFC; Mendes LSC; Ivantes CAP; Codes L; Borges VFAE; Pace FHL; Pessôa MG; Signorelli IV; Coral GP; Bittencourt PL; Fucuta P; Filho RJC; Ferraz MLG
Eur J Gastroenterol Hepatol; 2024 May; 36(5):628-635. PubMed ID: 38555601
[TBL] [Abstract][Full Text] [Related]
19. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
20. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
